Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2019 Jul 2;144:106353. doi: 10.1016/j.prostaglandins.2019.106353

Figure 6. Liver and epididymal fat pad mass in mice treated with EP3 antagonist.

Figure 6.

The effect of EP3 antagonist, DG-041, on tissue weight was measured in 21 week old CB6F1 mice fed control, HFD, or VHFD. A. Increasing amounts of dietary fat increased liver mass in vehicle treated mice (One-way ANOVA test for linear trend, P = 0.0094). DG-041 did not have a significant effect on the weight of the liver (Two-way ANOVA effect of drug, P = 0.0984), except in mice fed control diet (post-hoc comparison, P = 0.0047). N = 4 control + vehicle, 3 control + DG-041, 4 HFD + vehicle, 4 HFD + DG-041, 4 VHFD + vehicle, 4 VHFD + DG-041. B. Dietary fat affected epididymal fat pad mass (Two-way ANOVA effect of diet, P = 0.0142). DG-041 did not significantly affect the weight of the epididymal fat pads (Two-way ANOVA effect of drug, P = 0.6469). N = 4 control + vehicle, 3 control + DG-041, 4 HFD + vehicle, 4 HFD + DG-041, 4 VHFD + vehicle, 5 VHFD + DG-041. Values are expressed as mean ± SEM.